Bionomics Limited

ABN 53 075 582 740

BIONOMICS LIMITED

ASX Results Announcement, Directors' Report and Financial Statements – 30 June 2016

Lodged with the ASX under Listing Rule 4.3A

Contents

BIONOMICS LIMTED
Year ended 30 June 2016
(previous corresponding period: year ended 30 June 2015)

Results for Announcement to the Market

				$
Cash and cash equivalents as at 30 June 2016 from 30 June 2015	increased by	71.14%	to	45,450,382
Net operating and investing cash outflows for the period	increased by	407.27%	to	14,255,298
Revenue from ordinary activities	increased by	19.28%	to	8,143,288
Revenue and other income	increased by	30.76%	to	21,727,915
Loss from ordinary activities after tax attributable to members	decreased by	2.01%	to	16,608,757

NTA Backing

	2016	**2015**
Net tangible asset backing per ordinary share	6.5 cents	4.4 cents

Explanation of cash and cash equivalents position as at 30 June 2016:
The closing cash and cash equivalents position is in line with expectations and reflects the Company's continued investment in research and development. Additional capital was received during the year to fund the BNC210 clinical trial in Post Traumatic Stress Disorder.

Explanation of net movement in operating and investing cash outflows:
The net movement includes an increase in core R&D expenditure on the Company's clinical programs BNC210 and BNC101 in 2016 and the continued development of the product pipeline. Receipts from customers reflect the receipt of funds from Merck (known as MSD outside the USA & Canada), contract services and sales of libraries by our wholly-owned subsidiaries Neurofit and Prestwick.

Explanation of revenue from ordinary activities:
Revenue consists of payments under Bionomics' agreement with MSD, contract service revenue of Bionomics' wholly-owned subsidiaries Neurofit and Prestwick, rental and interest income received as a result of ordinary activities and other income including the government's R&D Tax Incentive in Australia and similar incentives for the subsidiaries.

Explanation of net profit from ordinary activities after tax:
The current year loss reflects the Company's investment in research and development activities.

Dividends/Distributions
Bionomics Limited does not propose to pay any dividend for the year ended 30 June 2016.

ASX ANNOUNCEMENT
9 August 2016

BIONOMICS REPORTS FULL YEAR FINANCIAL RESULTS

Adelaide, Australia: Bionomics Limited (ASX:BNO, OTCQX:BNOEF), today announced its financial results for the 12 months to 30 June 2016.

Key Points – Financial

- Cash at 30 June 2016 was $45,450,382, an increase of $26,558,006 over the 30 June 2015 balance.
- Revenue and other income for the period was $21,727,915, compared with $16,616,405 for the period to 30 June 2015.
- The operating loss after tax of the Group for the period was $16,608,757 and reflects the Company's continued execution of its business plan.

Operational Highlights

BNC210 made strong progress in the clinic

- Positive clinical trial results were reported in September 2015 which supported the mechanism of action of BNC210 and continued to indicate that BNC210 was safe and well tolerated.
- In June 2016 Bionomics announced the completion of dosing in a Phase 2 trial in patients with generalised anxiety disorder which is evaluating the capacity of BNC210 to engage brain systems relevant to anxiety using functional magnetic resonance imaging (fMRI). The endpoints of the trial include changes in cerebral perfusion and in task-related brain activity using the emotional faces task. The clinical trial has been conducted at The Institute of Psychiatry, Psychology & Neuroscience at King's College in London and data is anticipated by 30 September 2016.
- In June 2016 Bionomics commenced a multi-centre, placebo controlled, double-blinded Phase 2 clinical trial in patients with Post Traumatic Stress Disorder (PTSD). The clinical trial will be conducted in Australia and New Zealand.
- BNC210 is a novel, proprietary negative allosteric modulator of the alpha-7 nicotinic acetylcholine receptor, or the α7 receptor, in development for the treatment of anxiety disorders, Post Traumatic Stress Disorder (PTSD) and depression. In six completed Phase 1 clinical trials, BNC210 has demonstrated safety and tolerability in over 190 healthy subjects and shown initial indications of efficacy in the absence of side effects such as sedation, memory loss, impairment of motor co-ordination and potential for addiction.

Bionomics continues to develop its cancer drug pipeline

- In April 2016 a Phase 1 clinical trial of Bionomics lead cancer stem cell drug candidate BNC101 commenced in patients with metastatic colon cancer. This followed a successful IND submission to the US FDA in July 2015.
- New BNC105 data were presented at major international cancer conferences AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and the annual American Association for Cancer Research (AACR) conference in April 2016. The data demonstrated that BNC105 synergised with immune-oncology agents by re-activating the immune response to tumours and potentiating their anti-tumour activity.

Focus on key relationship with MSD and partnerships

- In October 2015 Merck & Co (known as MSD outside the US and Canada) became shareholders of Bionomics with a US$9 million investment.
- Also in October 2015 MSD extended the pain program Option and License Agreement.
- In November 2015 the Bionomics and MSD Symposium focused on the latest Alzheimers Disease research.
- In June 2016 Bionomics received its share (US$736,815) of the upfront payment under a licensing agreement for the PRMT5 project with MSD under its collaborative arrangements with the Co-operative Research Centre for Cancer Therapeutics.

Outlook

Bionomics is in a strong position to progress its development programs and the Company continues to focus on its important relationship with MSD in pain and cognition to bring new treatments to patients suffering chronic pain and sufferers of memory impairment including those with ADHD, Alzheimer's Disease, Parkinson's disease and Schizophrenia.

We are advancing the development of BNC210 to treat anxiety and PTSD. We have an ongoing Phase 2 clinical trial of BNC210 in patients with PTSD and anticipate reporting data from a Phase 2 clinical trial of BNC210 in patients with generalized anxiety disorder by 30 September 2016.

We also intend to advance the development of BNC101 to treat solid tumors by targeting cancer stem cells. First data from the ongoing BNC101 clinical trial in patients with colon cancer is anticipated in 2017.

Bionomics will seek further opportunities to execute its partnership strategy through new licensing agreements for assets across its portfolio of drug candidates.

FOR FURTHER INFORMATION PLEASE CONTACT:

DR DEBORAH RATHJEN
CEO & MANAGING DIRECTOR
BIONOMICS LIMITED
Ph: +61 8 8354 6101

MS MELANIE YOUNG
CFO
BIONOMICS LIMITED
Ph: + 61 8 8354 6100

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 (α7) nicotinic acetylcholine

receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016.   Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

www.bionomics.com.au

Factors Affecting Future Performance
This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.

Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this announcement.